Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique

Drug Development and Industrial Pharmacy

Volumn 36, Issue 8, 2010, Pages 917-925

  Maghsoodi, Maryam ^a   Sadeghpoor, Fatemeh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aerosil; Enteric microparticles; Eudragit S100; Piroxicam; Spherical crystallization

Indexed keywords

AEROSIL; EUDRAGIT; PIROXICAM; EXCIPIENT; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; MICROSPHERE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMETHACRYLIC ACID DERIVATIVE; SILICON DIOXIDE; SUSPENSION;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMIDITY; HYDROGEN BOND; INFRARED SPECTROSCOPY; PH; X RAY POWDER DIFFRACTION; CHEMISTRY; COMPARATIVE STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; PARTICLE SIZE; PROCEDURES; SOLUBILITY; SURFACE PROPERTY; SUSPENSION; TIME; X RAY CRYSTALLOGRAPHY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DIFFUSION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MICROSPHERES; PARTICLE SIZE; PIROXICAM; POLYMETHACRYLIC ACIDS; SILICON DIOXIDE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; SUSPENSIONS; TIME FACTORS;

EID: 77954203501     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903585127     Document Type: Article

References (44)

1. Dahl SL, Ward JR. (1982). Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy, 2:80-89
2. Mckellar QA, May SA, Lees P. (1991). Pharmacology and therapeutics of non-steroidal anti-inflammatory drugs in the dog and cat: 2 Individual agents. J Small Anim Pract, 32:225-235
3. Galbraith EA, Mckellar QA. (1991). Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Vet Rec, 128:561-565
4. Streubel A, Siepmann J, Bodmeier R. (2006). Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol, 6:501-508
5. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ibuki R, et al. (2006). Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): In vivo evaluation. J Control Release, 112:51-56
6. Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47-60.
7. Majerik V, Charbit G, Badens E, Horvath G, Szokonya L, Bosc N, et al. (2007). Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. J Supercrit Fluids, 40:101-110
8. Prabhu S, Ortega M, Ma Ch. (2005). Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int J Pharm, 301:209-216
9. Sumano H, Devizcaya A. (1996). Tolerance and clinical evaluation of piroxicam in dogs. Canine Pract, 21:16-19
10. Bjorkman DJ. (1996). Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med, 101:S25-S32.
11. Chiou WL, Riegelman S. (1970). Oral absorption of griseofulvin in dogs: Increased absorption via solid dispersion in polyethylene glycol 6000. J Pharm Sci, 59:937-942
12. Sekiguchi K, Obi N. (1961). Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull, 9:866-872
13. Goldberg AH, Gibaldi M, Kamig JL. (1965). Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature. J Pharm Sci, 54:1145-1148
14. Chiou WL, Reigelman S. (1971). Pharmaceutical applications of solid dispersion systems. J Pharm Sci, 60:1281-1302
15. Ford JL. (1986). The current status of solid dispersions. Pharm Acta Helv, 61:69-88.
16. Kawashima Y, Okumura M, Takenaka H. (1982). Spherical crystallization: Direct spherical agglomeration of salicylic acid crystals during crystallization. Science, 216:1127-1128
17. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Hino T. (2003). Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process. Powder Technol, 130:283-289
18. Maghsoodi M, Hassan-zadeh D, Barzegar-jalali M, Nokhodchi A, Martin G. (2007). Improved compaction and packing properties of naproxen agglomerated crystals obtained by spherical crystallization technique. Drug Dev Ind Pharm, 33:1216-1224
19. Cui FD, Kawashima Y, Takeuchi H, Niwa T, Hino T. (1996). Preparation of controlled releasing acrylic polymer microparti-cles of acebutolol hydrochloride and microparticles with sodium alginate in a polymeric spherical crystallization system. Chem Pharm Bull, 44:837-842 (Pubitemid 26149886)
20. Maghsoodi M, Esfahani M. (2009). Preparation of microparticles of naproxen with Eudragit RS and Talc by spherical crystallization technique. Pharm Dev Technol, 14(4):442-450
21. Niwa T, Takeuchi H, Hino T, Itoh A, Kawashima Y, Kiuchi K. (1994). Preparation of agglomerated crystals for direct tablet-ting and microencapsulation by the spherical crystallization technique with a continuous system. Pharm Res, 11:478-484
22. Kawashima Y, Niwa T, Kakeuchi H, Hino T, Itoh Y. (1991). Preparation of multiple unit hollow microparticles (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior (in vitro). J Control Release, 16:279-290
23. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. (1993). Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with DL-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method and the drug release behavior. J Control Release, 25:89-98.
24. Kawashima Y. (1989). Spherical crystallization as a novel particle design technique for oral drug delivery system. Chin Pharm J, 41:163-172
25. Cui FD, Wang X, Yang MS, Pang XJ. (2001). Studies on the preparation of sustained-release microparticles by spherical crystallization technique. In: The 18th symposium on particulate preparations and designs, Japan, 209-214
26. Pilpel N. (1964). The flow properties of magnesia. J Pharm Pharmacol, 16:705-716
27. Carr RL. (1965). Evaluation flow properties of solids. Chem Eng, 72:163-168
28. Carr RL. (1965). Classify flow properties of solids. Chem Eng, 72:69-72.
29. Re MI, Biscans B. (1999). Preparation of microparticles of Keto-profen with acrylic polymers by a quasi-emulsion solvent diffusion method. Powder Technol, 101:120-133
30. Kachrimanis K, Nikolakakis I, Malamataris S. (2000). Spherical crystal agglomeration of ibuprofen by the solvent-change technique in presence of methacrylic polymers. J Pharm Sci, 89(2):250-258
31. Zaniboni HC, Fell JT, Collett JH. (1995). Production and characterization of enteric beads. Int J Pharm, 125:151-155
32. Thomopson CJ, Hansford D, Higgin S, Rostron C, Hutcheon CA, Munday DL. (2007). Evaluation of ibuprofen-loaded micro-particles prepared from novel copolyesters. Int J Pharm, 329:53-61.
33. Yang MS, Cui F, You B, Fan Y, Wang L, Yue P, et al. (2003). Preparation of sustained-release nitrendipine microparticles with Eudragit RS and Aerosil using quasi-emulsion solvent diffusion method. Int J Pharm, 259:103-113
34. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. (1992). Hollow microparticles for use as a floating controlled drug delivery system in the stomach. J Pharm Sci, 81(2):135-140
35. Gennaro AR. (1990). Remington's pharmaceutical sciences. XVIII ed. Easton, PA: Mack Publishing Company, 1116.
36. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. (1999). Properties of solid dispersions of piroxicam in polyvi-nylpyrrolidone. Int J Pharm, 181:143-151
37. Mihalic M. (1986). Piroxicam. In: Florey, K, ed. Analytical profiles of drug substances, vol.15. London: Academic Press, 509-531
38. Vrecer F, Vrbinc M, Meden A. (2003). Characterization of piroxicam crystal modifications. Int J Pharm, 256:3-15.
39. Gao Y, Cui F, Guan Y, Yang L, Wang Y, Zhang L. (2006). Preparation of roxithromycin-polymeric microparticles by the emulsion solvent diffusion method for taste masking. Int J Pharm, 318:62-69
40. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. (1996). Properties of solid dispersions of piroxicam in polyvi-nylpyrrolidone K-30. Int J Pharm, 143:59-66.
41. Broman E, Khoo C, Taylor LS. (2001). A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water-soluble drug. Int J Pharm, 222:139-151
42. Dordunoo SK, Ford JL, Rubinstein MH. (1991). Preformula-tion studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm, 17:1685-1713
43. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C, et al. (2002). Characterization of carmazepinegelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci, 91:699-707.
44. Albertinia B, Passerinia N, González-Rodŕguezb ML, Perissuttic B, Rodrigueza L. (2004). Effect of Aerosil on the properties of lipid controlled release microparticles. J Control Release, 100:233-246